Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy.
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!
Nuvalent’s neladalkib posts 44% response rate in ALK-positive solid tumors beyond lung cancer
Discover how Nuvalent’s neladalkib delivered a 44% response rate in ALK-positive solid tumors beyond NSCLC and what this means for oncology.
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer
Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape.
Is GeoVax’s 11.9m share move a warning sign for investors—Or the setup for a surprise comeback?
Find out how GeoVax Labs’ 11.9 M-share sale is testing investor faith in its vaccine pipeline and what it means for the small-cap biotech’s future.
Can Roche’s 62% success rate in breast cancer trials spark the next oncology breakthrough?
Roche’s new oral breast-cancer therapy cut disease-progression risk by up to 62% in late-stage trials. Find out how it could reshape treatment in 2025.
Can an FDA approval move the needle for Alembic Pharmaceuticals stock?
Alembic Pharmaceuticals gains USFDA approval for a key injectable in the U.S. Find out how this regulatory win influences its stock, valuations, and pipeline story.